Recently, it has been described that CD40 stimulation increases OXPHOS and glycolysis in CLL cells, leading venetoclax resistance that can be counteracted by OXPHOS and mTOR inhibitors [31]. The gene discussed is MTOR; the disease is B-cell chronic lymphocytic leukemia.